| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 215.22% | JP Morgan | $32 → $29 | Maintains | Overweight |
| 10/18/2023 | 258.7% | Wedbush | → $33 | Reiterates | Outperform → Outperform |
| 08/09/2023 | 378.26% | HC Wainwright & Co. | $54 → $44 | Maintains | Buy |
| 03/17/2023 | 486.96% | HC Wainwright & Co. | → $54 | Reiterates | → Buy |
| 03/16/2023 | 247.83% | JP Morgan | $34 → $32 | Maintains | Overweight |
| 03/16/2023 | 258.7% | Wedbush | $45 → $33 | Maintains | Outperform |
| 05/13/2022 | 541.3% | SVB Leerink | $60 → $59 | Maintains | Outperform |
| 12/13/2021 | 486.96% | HC Wainwright & Co. | $37 → $54 | Maintains | Buy |
| 11/12/2021 | 486.96% | SVB Leerink | $55 → $54 | Maintains | Outperform |
| 08/13/2021 | 497.83% | SVB Leerink | $56 → $55 | Maintains | Outperform |
| 05/19/2021 | 389.13% | SVB Leerink | $60 → $45 | Maintains | Outperform |
| 05/05/2021 | 302.17% | HC Wainwright & Co. | → $37 | Initiates Coverage On | → Buy |
| 04/06/2021 | 552.17% | SVB Leerink | $37 → $60 | Maintains | Outperform |
| 11/19/2020 | 302.17% | SVB Leerink | $36 → $37 | Maintains | Outperform |
| 10/08/2020 | 389.13% | Baird | → $45 | Initiates Coverage On | → Outperform |
| 08/18/2020 | 334.78% | JP Morgan | → $40 | Initiates Coverage On | → Overweight |
| 08/18/2020 | 389.13% | Wedbush | → $45 | Initiates Coverage On | → Outperform |
| 08/18/2020 | 291.3% | SVB Leerink | → $36 | Initiates Coverage On | → Outperform |
| 08/18/2020 | 443.48% | Piper Sandler | → $50 | Initiates Coverage On | → Overweight |
What is the target price for ITeos Therapeutics (ITOS)?
The latest price target for ITeos Therapeutics (NASDAQ: ITOS) was reported by JP Morgan on November 13, 2023. The analyst firm set a price target for $29.00 expecting ITOS to rise to within 12 months (a possible 215.22% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ITeos Therapeutics (ITOS)?
The latest analyst rating for ITeos Therapeutics (NASDAQ: ITOS) was provided by JP Morgan, and ITeos Therapeutics maintained their overweight rating.
When is the next analyst rating going to be posted or updated for ITeos Therapeutics (ITOS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ITeos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ITeos Therapeutics was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
Is the Analyst Rating ITeos Therapeutics (ITOS) correct?
While ratings are subjective and will change, the latest ITeos Therapeutics (ITOS) rating was a maintained with a price target of $32.00 to $29.00. The current price ITeos Therapeutics (ITOS) is trading at is $9.20, which is out of the analyst's predicted range.